Ana Vindel1, Pilar Trincado1, Oscar Cuevas1, Carmen Ballesteros1, Emilio Bouza2, Emilia Cercenado3. 1. Servicio de Microbiología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. 2. Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain Department of Medicine, Facultad de Medicina, Universidad Complutense, Madrid, Spain. 3. Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain Department of Medicine, Facultad de Medicina, Universidad Complutense, Madrid, Spain emilia.cercenado@salud.madrid.org.
Abstract
OBJECTIVES: In Spain, despite the high rates of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA), the incidence of community-associated (CA) MRSA seems to be low on the basis of a small number of studies. We analysed the evolution of CA-MRSA in Spain from 2004 to 2012, and identified the clonal lineages and population structure. METHODS: The study included 8326 MRSA strains. Susceptibility to 18 antimicrobials was determined. Isolates were tested for the presence of mecA, Panton-Valentine leucocidin (PVL) and the arginine catabolic mobile element (ACME) by PCR, and typed by staphylococcal cassette chromosome mec, PFGE, spa, multilocus sequence typing and agr. RESULTS: Among the 8326 isolates, 246 (2.9%) were CA-MRSA. We identified genotypically 226 PVL-positive CA-MRSA isolates (88% agr type I, 10.2% agr type III and 1.8% agr type II) and 20 PVL-negative CA-MRSA isolates (all agr type I) from children and adults (82.1% from wounds) from 13 different geographical areas. A significant increase in the rates of CA-MRSA was observed when comparing 2004-07 (0.43%) with 2008-12 (5.44%). Resistance rates were as follows: only β-lactams, 84.5%; erythromycin, 12.8%; tetracycline, 8.8%; clindamycin, 4.9%; ciprofloxacin, 3.1%; fusidic acid, 2.0%; others, 0.4%; and multiresistant, 6.2% (six isolates USA300). The strains belonged to the PVL-positive clones ST8-IVc (69.9%), ST8-IVa-ACME-positive (USA300, 8.9%), ST8-IVa-ACME-negative (0.8%), ST30-IVc (4.5%), ST80-IVc (2.0%), ST5-IVc (1.2%) and others (ST59, ST72, ST88, ST642, ST1472 and ST1829; 4.5%) and to the PVL-negative ST398-V (8.1%). CONCLUSIONS: We confirm an increase in CA-MRSA in Spain, the predominance of the ST8-IVc clone, the emergence of the USA300 clone, a high genetic diversity among PVL-positive CA-MRSA isolates and the recent emergence of the pig-associated ST398-V clone.
OBJECTIVES: In Spain, despite the high rates of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA), the incidence of community-associated (CA) MRSA seems to be low on the basis of a small number of studies. We analysed the evolution of CA-MRSA in Spain from 2004 to 2012, and identified the clonal lineages and population structure. METHODS: The study included 8326 MRSA strains. Susceptibility to 18 antimicrobials was determined. Isolates were tested for the presence of mecA, Panton-Valentine leucocidin (PVL) and the arginine catabolic mobile element (ACME) by PCR, and typed by staphylococcal cassette chromosome mec, PFGE, spa, multilocus sequence typing and agr. RESULTS: Among the 8326 isolates, 246 (2.9%) were CA-MRSA. We identified genotypically 226 PVL-positive CA-MRSA isolates (88% agr type I, 10.2% agr type III and 1.8% agr type II) and 20 PVL-negative CA-MRSA isolates (all agr type I) from children and adults (82.1% from wounds) from 13 different geographical areas. A significant increase in the rates of CA-MRSA was observed when comparing 2004-07 (0.43%) with 2008-12 (5.44%). Resistance rates were as follows: only β-lactams, 84.5%; erythromycin, 12.8%; tetracycline, 8.8%; clindamycin, 4.9%; ciprofloxacin, 3.1%; fusidic acid, 2.0%; others, 0.4%; and multiresistant, 6.2% (six isolates USA300). The strains belonged to the PVL-positive clones ST8-IVc (69.9%), ST8-IVa-ACME-positive (USA300, 8.9%), ST8-IVa-ACME-negative (0.8%), ST30-IVc (4.5%), ST80-IVc (2.0%), ST5-IVc (1.2%) and others (ST59, ST72, ST88, ST642, ST1472 and ST1829; 4.5%) and to the PVL-negative ST398-V (8.1%). CONCLUSIONS: We confirm an increase in CA-MRSA in Spain, the predominance of the ST8-IVc clone, the emergence of the USA300 clone, a high genetic diversity among PVL-positive CA-MRSA isolates and the recent emergence of the pig-associated ST398-V clone.
Authors: K Kaïret; E Ho; D Van Kerkhoven; J Boes; S Van Calenbergh; L Pattyn; P Lemay Journal: Eur J Clin Microbiol Infect Dis Date: 2017-01-03 Impact factor: 3.267
Authors: Megan R Earls; David C Coleman; Gráinne I Brennan; Tanya Fleming; Stefan Monecke; Peter Slickers; Ralf Ehricht; Anna C Shore Journal: Front Microbiol Date: 2018-07-04 Impact factor: 5.640
Authors: Olouwafemi Mistourath Mama; Modou Dieng; Bocar Hanne; Laura Ruiz-Ripa; Codou Gueye Mar Diop; Carmen Torres Journal: BMC Vet Res Date: 2019-11-04 Impact factor: 2.741
Authors: M S Aung; H Zi; K M Nwe; W W Maw; M T Aung; W W Min; N Nyein; M Kawaguchiya; N Urushibara; A Sumi; N Kobayashi Journal: New Microbes New Infect Date: 2016-01-01
Authors: Ahmed Esmael; Mervat G Hassan; Mahmoud M Amer; Soheir Abdelrahman; Ahmed M Hamed; Hagar A Abd-Raboh; Mohamed F Foda Journal: Saudi J Biol Sci Date: 2019-11-20 Impact factor: 4.219